NCT06939166View on ClinicalTrials.gov

Universal Chimeric Antigen Receptor T-Cell （UCAR T-cell） Therapy Targeting CD19/B Cell Maturation Antigen （CD19/BCMA） in Patients With r/r Neurological Autoimmune Diseases

EARLY_PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2025

Primary Completion Date

April 30, 2026

Study Completion Date

October 31, 2027

Conditions

Neuromyelitis Optica Spectrum DisordersMyasthenia GravisMultiple SclerosisChronic Inflammatory Demyelinating PolyradiculoneuropathyAutoimmune Encephalitis

Interventions

DRUG

UCAR T-cell

Universal allogeneic anti-CD19/BCMA CAR T-cells

Trial Locations (1)

Unknown

Tianjin Huanhu Hospital, Tianjin

All Listed Sponsors

collaborator

Shanghai Xiniao Biotech Co., Ltd.

INDUSTRY

lead

Tianjin Huanhu Hospital

OTHER